Financing Drugs in South-East Asia - Report of the First Meeting of the WHO/SEARO Working Group on Drug Financing, Korat, Thailand, 26-28 November 1996 - Health Economics and Drugs Series No. 004
(1997; 72 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoExecutive summary
Abrir esta carpeta y ver su contenido1. Introduction
Abrir esta carpeta y ver su contenido2. Country presentations on drug financing
Abrir esta carpeta y ver su contenido3. Korat provincial field visit
Abrir esta carpeta y ver su contenido4. Drug financing issues
Abrir esta carpeta y ver su contenido5. Country priorities for drug financing
Abrir esta carpeta y ver su contenido6. Priorities for work group action
Abrir esta carpeta y ver su contenido7. Conclusions and recommendations
Ver el documentoAnnex A. Agenda
Ver el documentoAnnex B. List of participants
Ver el documentoAnnex C. List of documents
Ver el documentoAnnex D. Message from Regional Director, WHO South-East Asia Region
Cerrar esta carpetaAnnex E. Evaluation of the meeting. Priorities for the Working Group
Ver el documento1. Evaluation of the meeting
Ver el documento2. Priorities for the next Working Group meeting
 

2. Priorities for the next Working Group meeting

Participants indicated the following priorities:

   

Rating for priorities

Topic

n

4 = very high

3 = high

2 = low

1 = very low

1. Public financing

 

1.1 Health and drug financing indicators

10

7

3

0

0

 

1.2 Experiences in increasing government health and drug budgets

10

5

3

2

0

2. Cost-sharing for health and drugs

 

2.1 Policies and guidelines

9

5

4

0

0

 

2.2 Report of experiences/lessons from cost-sharing systems

7

3

4

0

0

3. Insurance for health and drugs

 

3.1 Alternative insurance systems

8

2

6

0

0

 

3.2 Mechanisms for providing drugs through insurance

6

3

2

1

0

4. The use of international loans in the pharmaceutical sector

6

3

2

1

0

5. Drug pricing policies and mechanisms

 

5.1 Control of drug manufacturers' prices

8

5

0

3

0

 

5.2 Distribution mark-ups (wholesale and retail margins)

8

2

3

3

0

 

5.3 Use of generic drugs to promote competition

8

3

4

1

0

 

5.4 Cost containment in the drug sector

8

3

5

0

0

6. Financing mechanisms to improve:

 

6.1 Drug selection

9

3

5

1

0

 

6.2 Drug supply

7

3

1

3

0

 

6.3 Drug quality assurance

8

2

6

0

0

 

6.4 Drug distribution

6

3

3

0

0

 

6.5 Rational use of drugs

7

4

3

0

0

7. Health reform and global change

 

7.1 Drugs and health sector reform

7

4

3

0

0

 

7.2 Impact of globalization WTO/TRIPS on drugs

8

3

4

1

0

 

7.3 Public-private roles in pharmaceutical sector

8

6

2

0

0

Questions

1. For field visits, should there be:

⇒ more visits/different types of facilities (5)*
⇒ same number of visits (4)
⇒ no field visit (0)

(*) Number in brackets indicates the number of responses

2. For prepared presentations on specific topics, should there be:

⇒ more presentations (2)
⇒ same presentations (6)
⇒ fewer presentations (0)

3. For group discussions, should there be:

⇒ more time (5)
⇒ same amount of time (3)
⇒ less time (0)

4. Other comments:

⇒ More time for presentation and discussion, and for discussion on the field visits.
⇒ Participants should know what to prepare, etc. at least one month beforehand.
⇒ Health economics experts should be invited to the next meeting and presentation.

* * *

Ir a la sección anterior
 

Última actualización: le 24 abril 2012